Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

January 16, 2018; 90 (3) Article

Comparative effect of statins on the risk of incident Alzheimer disease

Liliya Sinyavskaya, Serge Gauthier, Christel Renoux, Sophie Dell'Aniello, Samy Suissa, Paul Brassard
First published December 15, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004818
Liliya Sinyavskaya
From the Centre for Clinical Epidemiology (L.S., C.R., S.D., S.S., P.B.), Jewish General Hospital; McGill University Research Centre for Studies in Aging (S.G.), Douglas Mental Health University Institute; and Departments of Neurology and Neurosurgery (C.R.) and Medicine and Epidemiology, Biostatistics, and Occupational Health (C.R., S.S., P.B.), McGill University, Montreal, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serge Gauthier
From the Centre for Clinical Epidemiology (L.S., C.R., S.D., S.S., P.B.), Jewish General Hospital; McGill University Research Centre for Studies in Aging (S.G.), Douglas Mental Health University Institute; and Departments of Neurology and Neurosurgery (C.R.) and Medicine and Epidemiology, Biostatistics, and Occupational Health (C.R., S.S., P.B.), McGill University, Montreal, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christel Renoux
From the Centre for Clinical Epidemiology (L.S., C.R., S.D., S.S., P.B.), Jewish General Hospital; McGill University Research Centre for Studies in Aging (S.G.), Douglas Mental Health University Institute; and Departments of Neurology and Neurosurgery (C.R.) and Medicine and Epidemiology, Biostatistics, and Occupational Health (C.R., S.S., P.B.), McGill University, Montreal, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Dell'Aniello
From the Centre for Clinical Epidemiology (L.S., C.R., S.D., S.S., P.B.), Jewish General Hospital; McGill University Research Centre for Studies in Aging (S.G.), Douglas Mental Health University Institute; and Departments of Neurology and Neurosurgery (C.R.) and Medicine and Epidemiology, Biostatistics, and Occupational Health (C.R., S.S., P.B.), McGill University, Montreal, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samy Suissa
From the Centre for Clinical Epidemiology (L.S., C.R., S.D., S.S., P.B.), Jewish General Hospital; McGill University Research Centre for Studies in Aging (S.G.), Douglas Mental Health University Institute; and Departments of Neurology and Neurosurgery (C.R.) and Medicine and Epidemiology, Biostatistics, and Occupational Health (C.R., S.S., P.B.), McGill University, Montreal, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Brassard
From the Centre for Clinical Epidemiology (L.S., C.R., S.D., S.S., P.B.), Jewish General Hospital; McGill University Research Centre for Studies in Aging (S.G.), Douglas Mental Health University Institute; and Departments of Neurology and Neurosurgery (C.R.) and Medicine and Epidemiology, Biostatistics, and Occupational Health (C.R., S.S., P.B.), McGill University, Montreal, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Comparative effect of statins on the risk of incident Alzheimer disease
Liliya Sinyavskaya, Serge Gauthier, Christel Renoux, Sophie Dell'Aniello, Samy Suissa, Paul Brassard
Neurology Jan 2018, 90 (3) e179-e187; DOI: 10.1212/WNL.0000000000004818

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Comment

Downloads
505

Share

  • Article
  • Figures & Data
  • Info
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective To investigate whether fungus-derived statins are associated with a lower risk of incident Alzheimer disease (AD) compared with synthetic statins using real-world clinical practice data.

Methods We identified a population-based retrospective cohort of patients aged ≥60 years newly prescribed a statin between January 1, 1994, and December 31, 2012, and followed until March 31, 2015, using the UK Clinical Practice Research Datalink. Statins were consecutively classified according to their type, lipophilicity, and potency. For each group, we calculated the crude AD incidence rates per 1,000 person-years. Time-dependent Cox proportional hazards models adjusted for propensity score deciles were used to estimate hazard ratios (HRs) with 95% confidence interval (CIs) of incident AD associated with different statin categories.

Results Over the 18-year study period, we identified 465,085 statin users, including 7,669 patients who developed AD during 2,891,268 person-years of follow-up (incidence rate 2.65 [95% CI 2.59–2.71] per 1,000 person-years). Compared to synthetic, fungus-derived statins were associated with an increased risk of AD (HR 1.09, 95% CI 1.03–1.15). Lipophilic statins also were associated with higher AD risk (HR 1.18, 95% CI 1.09–1.27) compared to hydrophilic statins, while statin potency did not modify the risk of AD (adjusted HR 1.03, 95% CI 0.98–1.08). The risk was further reduced in sensitivity analyses.

Conclusion Fungus-derived and lipophilic statins were not associated with decreased incidence of AD compared to synthetic and hydrophilic statins. The modest variations in the risk of incident AD observed between statin characteristics needs to be evaluated in future studies on their possible heterogeneous neuroprotective effect.

Glossary

AD=
Alzheimer disease;
CI=
confidence interval;
CPRD=
UK Clinical Practice Research Datalink;
HR=
hazard ratio;
IQR=
interquartile range;
LLD=
lipid-lowering drug;
PS=
propensity score;
UTS=
up-to-standard

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Received February 20, 2017.
  • Accepted in final form September 19, 2017.
  • Copyright © 2017 American Academy of Neurology
View Full Text

AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)

Non-AAN Member subscribers: Sign in with subscriber credentials

Log in using your username and password

Forgot your user name or password?

Purchase access

AAN members must change their passwords on the AAN site

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info

More Online

CME Course

Related Articles

  • Statin use and risk of Alzheimer disease

Topics Discussed

  • Alzheimer's disease
  • Cohort studies
  • Risk factors in epidemiology

Alert Me

  • Alert me when this article is cited
  • Alert me if a correction is posted
  • Alert me when eletters are published
Advertisement
Neurology: 92 (7)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2019 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise